alexa Primary Monosymptomatic Nocturnal Enuresis: Monotherapy Vs. Combination Therapy
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

12th Global Nephrologists Annual Meeting
June 26-28, 2017 London, UK

Sharifiaghdas F, Sharifiaghdas S and Taheri M
Shahid Beheshti University of Medical Sciences, Iran
Labbafinejad Hospital, Iran
Posters & Accepted Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959-C1-040
Objective: To evaluate the clinical results of monotherapy with combination therapy in treatment of Primary Monosymptomatic Nocturnal Enuresis (PMNE) in children. Patients & Methods: Between December 2008 and May 2013, we reviewed the records of 176 children with PMNE. The monotherapy group received 120 micrograms of desmopressin melt whereas the combination therapy group received 120 micrograms of desmopressin melt plus 1-2 mg oral tablet of tolterodine. The degree of response was evaluated at 1-3 months during the treatment and 6 months after complete cessation of treatment protocol. Results: Among 176 children, 84 and 92 patients received monotherapy and combination therapy, respectively. There were no statistical differences in gender, age, or baseline monthly frequency of PMNE between the two groups. At baseline, patients had an overall mean of 23.6±5.6 wet nights per month, which decreased to 10.8±5.6 and 7.3±5.3 in monotherapy group and 8.9±9.5 and 3.3±4.9 in combination therapy group at 1 and 3 months after treatment. The rates of Complete plus Partial Response to treatment at 1 and 3 months for monotherapy and combination therapy group were 63.1% and 73.9% vs. 72.5% and 93.47% (P value 0.12 vs. 0.006). The relapse of PMNE 6 months after complete cessation of treatment was 16.39% and 9.09% for monotherapy vs. combination therapy group. Conclusion: This study supports the efficacy of combination therapy with desmopressin melt plus oral tolterodine over monotherapy with desmopressin melt in the first-line treatment of PMNE in children.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version